US 12,215,101 B2
Pro drugs of PDE10 compounds
Sachin Mittal, Bridgewater, NJ (US); Jason W. Skudlarek, Audubon, PA (US); and Izzat T. Raheem, Doylestown, PA (US)
Assigned to Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed by Merck Sharp & Dohme LLC, Rahway, NJ (US)
Filed on Dec. 13, 2023, as Appl. No. 18/538,309.
Application 18/538,309 is a continuation of application No. 17/695,125, filed on Mar. 15, 2022, granted, now 11,919,894.
Claims priority of provisional application 63/162,333, filed on Mar. 17, 2021.
Prior Publication US 2024/0158388 A1, May 16, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 417/14 (2006.01)
CPC C07D 417/14 (2013.01) 3 Claims
 
1. A compound of structural Formula I:

OG Complex Work Unit Chemistry
or pharmaceutically acceptable salt thereof, wherein:
R1 is —C(O)OC1-6 alkyl, said alkyl optionally substituted with 1 to 3 groups of Ra, wherein the C1-6 alkyl of —C(O)OC1-6 alkyl is not t-butyl;
and
Ra is independently selected from the group consisting of C1-6 alkyl, OC1-6 alkyl, oxo, and halogen.